HCAT
Health Catalyst, Inc.
HCAT offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over HCAT overall, supported by stronger fundamentals and lower modeled downside.
HCAT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Healthy | |
| Unavailable |
HCAT's cash flow is currently healthy, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
HCAT PE Valuation
HCAT has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
HCAT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect HCAT's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over HCAT on the outlook, with more favorable earnings and revenue expectations.
HCAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.84 | -$1.25 |
| Q2 2026 | -$3.69 | -$2.18 |
| Q1 2026 | -$3.73 | -$2.58 |
| Q4 2025 | -$2.55 | -$1.40 |
| Q3 2025 | -$1.59 | -$0.25 |
| Q2 2025 | -$1.51 | -$0.02 |
| Q1 2025 | -$1.15 | +$0.69 |
| Q4 2024 | -$1.15 | +$0.94 |
HCAT lost $2.84 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over HCAT on earnings quality, reporting a profit while its opponent remains loss making.
HCAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $56.3M | -26% |
| Q2 2026 | $70.5M | -13% |
| Q1 2026 | $70.8M | -11% |
| Q4 2025 | $74.7M | -6.2% |
| Q3 2025 | $76.3M | 0% |
| Q2 2025 | $80.7M | +6.3% |
| Q1 2025 | $79.4M | +6.3% |
| Q4 2024 | $79.6M | +6% |
HCAT's revenue has slid since its 2025 peak: $56M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 89% | +112 points |
| Q2 2026 | -52% | -5.8 points |
| Q1 2026 | -150% | -125 points |
| Q4 2025 | -115% | -93 points |
| Q3 2025 | -23% | -5 points |
| Q2 2025 | -46% | -25 points |
| Q1 2025 | -25% | +5.1 points |
| Q4 2024 | -22% | +22 points |
HCAT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over HCAT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
HCAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2M | -$1.3M |
| Q2 2026 | -$70K | +$8.7M |
| Q1 2026 | $18.2M | +$18.6M |
| Q4 2025 | $9.6M | +$13.6M |
| Q3 2025 | -$719K | -113% |
| Q2 2025 | -$8.8M | -763% |
| Q1 2025 | -$390K | -104% |
| Q4 2024 | -$3.9M | +$15.4M |
HCAT's free cash flow has turned positive again: $26M over the past year, against −$14M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over HCAT on cash flow, with more consistent year-over-year improvement.
HCAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +2M shares |
| 1 year | +7.9% | +5.6M shares |
| 3 years | +34% | +19.2M shares |
| 5 years | +55% | +26.9M shares |
| Available history | +105% | +38.8M shares |
HCAT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $5M |
| Q4 2024 | — |
HCAT hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HCAT Net Leverage
HCAT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
HCAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.4 | Neutral |
| Stochastic | 9.3 | Oversold |
HCAT's weekly RSI is 37 (neutral) and its Stochastic is 9 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
HCAT PE vs Healthcare Sector
HCAT has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HCAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.65 | 18% below |
| 20 week MA | $1.79 | 24% below |
| 50 week MA | $1.79 | 24% below |
| 100 week MA | $2.93 | 54% below |
| 200 week MA | $6.18 | 78% below |
HCAT is in a downtrend: it's below all five of its weekly moving averages, and 78% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over HCAT on trend strength, trading above more of its moving averages.
HCAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $34.1 | $44.9 | +31% |
| 2021 | $44.9 | $39.5 | -12% |
| 2022 | $39.5 | $10.3 | -74% |
| 2023 | $10.3 | $9.26 | -10% |
| 2024 | $9.26 | $7.08 | -24% |
| 2025 | $7.08 | $2.42 | -66% |
| 2026 YTD | $2.42 | $1.36 | -44% |
HCAT has finished five years in a row lower, and it's down 44% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over HCAT on returns for 2026, with the stronger performance.